8-K - Coya Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement+4 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On January 29, 2026, Coya Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ S

Material Agreement

$4.40$11.1M$10.0M$1.1M

Source Document

3.02

. Unregistered Sales of Equity Securities. The information contained in Item 1.01 is hereby incorporated by reference in response to this Item 3.02 of Form 8-K.

Securities Issuance

7.01

Regulation FD Disclosure. On January 30, 2026, the Company issued a press release announcing its entry into the Securities Purchase Agreement. A copy of the pre

Regulation Fd

8.01

Other Events. The Company expects the proceeds from the Offering to allow it to fund its now accelerated commercial readiness plans with no impact to its cash r

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Securities Purchase Agreement, by and among the Company and the Purchasers

Exhibits Only

Source Document

Exhibits (3)

10.1

EX-10.1

8-K

99.1

EX-99.1